We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Mya C Schiess (McGovern Medical School at UTHealth, Houston, TX, USA) discusses promising findings from a phase I study (ClinicalTrials.gov identifier: NCT02611167), which was the focus of her presentation entitled: Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease. Questions 1. What is known about the role of inflammation in the […]
Mya C Schiess (McGovern Medical School at UTHealth, Houston, TX, USA) discusses promising findings from a phase I study (ClinicalTrials.gov identifier: NCT02611167), which was the focus of her presentation entitled: Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease. Questions 1. Could you tell us about the design of your phase […]
It was a pleasure to speak with Camille Carroll (University of Plymouth, Plymouth, UK) about her late-breaking presentation entitled: Simvastatin as a neuroprotective treatment for Parkinson’s disease (PD STAT): results of a double-blind, randomised, placebo-controlled futility study. ClinicalTrials.gov Identifier: NCT02787590. Questions What was the scientific rationale for investigating simvastatin as a neuroprotective treatment for Parkinson’s disease (PD)? (0:06) […]
Alisdair Coles (University of Cambridge, Cambridge, UK) shares exciting phase II findings that highlight the potential of retinoid-X receptor agonists to promote remyelination in relapsing-remitting multiple sclerosis. The interview focuses on his late-breaking presentation entitled: LB01.02 – Phase 2 clinical trial evidence that a retinoid-X receptor agonist promotes remyelination in people with relapsing-remitting multiple sclerosis. Study […]
It was a pleasure to hear from David Leppert (University Hospital Basel and University of Basel, Basel, Switzerland) on his late-breaking presentation about the exciting potential of neutrophil granulocyte markers in the cerebrospinal fluid to differentiate neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD) from multiple sclerosis (MS) in the acute disease phase. […]
We were fortunate to have the opportunity to speak with Tanya Simuni (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) following her session entitled: Update on Recent Clinical Trials – Parkinson’s Disease. Questions 1. Could you give us a brief overview of the role of α-synuclein in the pathogenesis of Parkinson’s disease (PD) and its potential […]
Klaus Seppi and Marina Peball (Innsbruck Medical University, Innsbruck, Austria) both kindly joined touchNEUROLOGY to share the promising results from their presentation entitled: Effects of Nabilone on Non-motor Symptoms of Parkinson’s Disease – A Randomised Placebo-controlled Study (The NMS-Nab Study). ClinicalTrials.gov identifier: NCT03769896. Questions 1. Could you give us a brief overview of non-motor symptoms in Parkinson’s disease […]
Georg Ebersbach (Movement Disorders Clinic, Beelitz-Heilstaetten, Beelitz, Germany) kindly took the time to talk us through the findings of his presentation entitled: Opicapone’s added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson’s disease: a post-hoc analysis of BIPARK-I and II. ClinicalTrials.gov identifiers for the […]
As always, we were pleased to have the opportunity to catch-up with valued editorial board member Heinz Reichmann (Technische Universität Dresden, Dresden, Germany), who spoke to us on the topic of the lecture he gave during the on-demand sessions entitled: The Gut Microbiome in the Pathogenesis of Parkinson’s Disease. Questions 1. Could you tell us […]
Get the latest clinical insights from touchNEUROLOGY